Skip to main content
. 2017 Jun 5;8:15663. doi: 10.1038/ncomms15663

Figure 3. ZA treatment does not affect other transporters in ZA and SIM-treated DC.

Figure 3

Levels of the indicated plasma-membrane-associated proteins are evaluated by western blotting in biotinylated extracts from untreated or 1 μM ZA and/or simvastatin (SIM) treated DC. Pancadherin is employed as a control of equal protein loading. The blots are representative of one out of the three experiments. (b) Activities of the indicated plasma-membrane-associated proteins are measured after immunopurification from the biotinylated extracts of DC treated, as shown in a. The results are expressed as nmoles hydrolysed phosphate (Pi)/min/mg proteins according to the previously prepared titration curve. The NHE1 activities and SLC4A1 activities are fluorimetrically measured, and the results are expressed as ΔpHi/min and arbitrary units, respectively. The bars represent the mean±s.e.m. of three experiments. None of the differences is statistically significant.